Literature DB >> 1606143

Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites.

J T Griffiths1, L H Phylip, J Konvalinka, P Strop, A Gustchina, A Wlodawer, R J Davenport, R Briggs, B M Dunn, J Kay.   

Abstract

The sequence requirements for HIV-1 proteinase catalyzed cleavage of oligopeptides containing two distinct types of junctions (-hydrophobic*hydrophobic- or -aromatic*Pro-) has been investigated. For the first type of junction (-hydrophobic*hydrophobic-) the optimal residues in the P2 and P2' positions were found to be Val and Glu, respectively, in accord with recent statistical analysis of natural cleavage sites [Poorman, R. A., Tomasselli, A. G., Heinrikson, R. L., & Kézdy, F. J. (1991) J. Biol. Chem. 266, 14554-14561]. For the -aromatic*Pro- type of junction, in the specific sequence context studied here, the value of Glu in the P2' position was again observed. An explanation for the inefficient cleavage observed for peptides with the sequence -Val-Tyr*Pro- has been provided from molecular modeling of the putative enzyme-substrate complex. A significant effect upon cleavage rates due to the amino acid in the P5 position has also been documented. While lysine in the P5 position in one sequence of the -hydrophobic*hydrophobic- type produces a peptide cleaved very efficiently (kcat greater than 15 s-1 for Lys-Ala-Arg-Val-Nle*p-nitrophenylalanine-P2'-Ala-Nle-NH2, for P2' = Glu, Gln, Ile, Val, or Ala), for substrates of the -aromatic*Pro- type, the P5 residue can exert either a positive or negative effect on cleavage rates. These results have again been interpreted in light of molecular modeling. We suggest that interaction of the substrate sequence on the periphery of the active site cleft may influence the match of the enzyme-substrate pair and, hence, control the efficiency of catalysis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606143     DOI: 10.1021/bi00137a015

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  22 in total

1.  Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease.

Authors:  C D Rosin; R K Belew; G M Morris; A J Olson; D S Goodsell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

2.  Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants.

Authors:  W Shao; L Everitt; M Manchester; D D Loeb; C A Hutchison; R Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

3.  HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites.

Authors:  Marc Potempa; Sook-Kyung Lee; Nese Kurt Yilmaz; Ellen A Nalivaika; Amy Rogers; Ean Spielvogel; Charles W Carter; Celia A Schiffer; Ronald Swanstrom
Journal:  J Mol Biol       Date:  2018-11-07       Impact factor: 5.469

4.  Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain.

Authors:  Michael E Abram; Michael A Parniak
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  Predicting cleavability of peptide sequences by HIV protease via correlation-angle approach.

Authors:  J J Chou
Journal:  J Protein Chem       Date:  1993-06

6.  Studies on the specificity of acetylaminoacyl-peptide hydrolase.

Authors:  C W Sokolik; T C Liang; F Wold
Journal:  Protein Sci       Date:  1994-01       Impact factor: 6.725

7.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Structure of equine infectious anemia virus proteinase complexed with an inhibitor.

Authors:  A Gustchina; J Kervinen; D J Powell; A Zdanov; J Kay; A Wlodawer
Journal:  Protein Sci       Date:  1996-08       Impact factor: 6.725

10.  Human immunodeficiency virus type-1 reverse transcriptase and ribonuclease H as substrates of the viral protease.

Authors:  A G Tomasselli; J L Sarcich; L J Barrett; I M Reardon; W J Howe; D B Evans; S K Sharma; R L Heinrikson
Journal:  Protein Sci       Date:  1993-12       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.